Novo Nordisk announced that Canadians with diabetes will soon have access to a once-weekly insulin injection, Awiqli, starting June 30. This marks the world’s first basal insulin injection that only needs to be taken weekly.
Approved by Health Canada in March, Awiqli will benefit both Type 1 and Type 2 diabetes patients, though it is especially advantageous for those with Type 2 diabetes.
Dr. Harpreet Bajaj from Diabetes Canada highlighted the reduced burden for patients who currently need daily injections. Clinical trials in Canada showed promising results, with patients eager for the new option. However, Type 1 diabetes patients will still require daily fast-acting insulin for mealtime.
Dr. Alexander Abitbol emphasized that weekly insulin could increase adherence to treatment, potentially reducing complications from high blood sugar levels. While the U.S. FDA has yet to approve Awiqli, the Canadian Drug Agency suggests funding it for Type 2 diabetes, conditional on a price reduction. Currently, Awiqli costs over $1,350 annually per patient. Novo Nordisk remains hopeful about coverage by private insurers, seeing positive early feedback.
